Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans
Open Access
- 19 November 2022
- journal article
- research article
- Published by Elsevier in Journal of Lipid Research
- Vol. 64 (1) , 100316
Abstract
No abstract availableKeywords
Funding Information
- F Hoffmann-La Roche Ltd
This publication has 56 references indexed in Scilit:
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Cardiovascular Protection by ApoE and ApoE-HDL Linked to Suppression of ECM Gene Expression and Arterial StiffeningCell Reports, 2012
- Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging studyAmerican Heart Journal, 2012
- Apolipoprotein E inhibits Toll-like receptor (TLR)-3- and TLR-4-mediated macrophage activation through distinct mechanismsBiochemical Journal, 2010
- The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosisJournal of Lipid Research, 2009
- Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular BenefitCardiovascular Drugs and Therapy, 2008
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Putting cholesterol in its place: apoE and reverse cholesterol transportJournal of Clinical Investigation, 2006
- Apolipoprotein E Binding to Low Density Lipoprotein Receptor-related Protein-1 Inhibits Cell Migration via Activation of cAMP-dependent Protein Kinase AJournal of Biological Chemistry, 2003
- Two-dimensional electrophoresis of plasma lipoproteins: Recognition of new apo A-I-containing subpopulationsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993